Abstract Submission :

Submit Abstract

Registration :

Register Now

Become a Sponsor/Exhibitor :

Become a Sponsor

Conference Organizing Committee :

View Committee

Register Now :

Register Now

Conference Program :

Brochure Download

SCIENTIFIC SESSIONS

  • Cancer Biology and Genetics
  • Cancer and Aging
  • Cancer Organoids
  • Cancer stem cells
  • CRISPR in Cancer Therapeutics
Read More

IMPORTANT DATES

Abstract Submission
January 31, 2023

Early Bird Registration
January 31, 2023

Register Now

Scientific Committee

Click on the image to view biography

Debananda Pati

Professor, Baylor College of Medicine, USA

Professor Pati is a highly accomplished cancer biologist who is an internationally recognized leader in the field of chromosomal cohesion and Separation and its role in carcinogenesis. He has a highly impressive track record not only in basic biology of chromosomal cohesion and separation, but devising novel and innovative approaches to target the cohesin pathway for treating refractory human cancers. He is widely recognized nationally and internationally as a creative and innovative scientist and is specifically recognized for his identification and targeting of the cohesin-protease, Separase for cancer therapy. Separase, an enzyme important for resolving chromosomal cohesion, is a novel oncogene and promoter of aneuploidy and tumorigenesis that Professor Pati demonstrated is an ideal target for cancer therapy. His laboratory was first to show that Separase is an oncogene and aneuploidy promoter. In a series of publications in high impact journals, Professor Pati and his colleagues demonstrated that overexpression of Separase in mouse models not only induces aneuploidy but also results in tumorigenesis.

Xiaoping Sun

Professor, University of Texas MD Anderson Cancer Center, USA

Xiaoping Sun completed his MD at Zhejiang Medical University, Hangzhou, China in 1984, and his PhD at Catholic University of Nijmegen, The Netherlands, and Shanghai Institute of Cell Biology, Chinese Academy of Sciences, Shanghai, China in 1994. He received postdoctoral fellowship training at the Salk Institute for Biological Studies, La Jolla, California, USA from 1994 to 1998. His medical residency in anatomical and clinical pathology was completed at Northwestern University Medical School, Chicago, Illinois, USA in 2002, and his hematopathology fellowship at The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA in 2003. He then became an assistant professor and subsequently associated professor and professor in the Department of Laboratory Medicine at UT MD Anderson. Besides his patient care clinical service in the core lab at UT MD Anderson, he runs a research lab that works on leukemogenesis, leukemia progression and drug resistance, B-cell acute lymphoblastic leukemia, and B-cell development.

Yun Gong

Professor, University of Texas MD Anderson Cancer Center, USA

Yun Gong received MD degree in 1984 and then finished her post-graduate Pathology training in 1989 at Zhejiang Medical University in China. She then worked as a post-doctor and Research Associate in the Shanghai Institute of Cell Biology, Chinese Academy of Sciences; Catholic University of Nijmegen, The Netherlands; and The Scripps Research Institute, La Jolla, California. From 1998 to 2002, she received her residency training in Anatomic and Clinical Pathology at Northwestern University Medical School in Chicago, followed by one-year cytopathology fellowship training at MD Anderson Cancer Center. From 2003, she became a faculty member at the Dept. of Pathology, MD Anderson Cancer Center, and currently is a Full Professor. She has numerous publications in the fields of breast cancer research and cytopathology (120 peer-review articles, 18 invited articles, 6 book chapters and 1 book, 118 abstracts). She is an important collaborator of two IBC research projects that were funded by Susan G. Komen Promise Grant. She is a Guest Editor of Breast Diseases: Year Book of Oncology since 2011, a member of the study section of MD Anderson Institutional Research Grant Program, and was a reviewer for NCI/NIH on Business Innovation Research Contract Proposals in 2009 and 2013.

Anissa Boumlic-Courtade

Associate Director , Merck, France

Anissa Boumlic-Courtade, PhD is Associate Director for the vaccine initiative in EMEA with Merck. She joined Merck in 2009 (formerly Millipore) after research experience in various institute including Pasteur Institute of Athens and the CNRS (National Center for Research, France). She has held various positions focused on downstream processing, virus safety, and monoclonal antibody and vaccine process development and manufacturing. She holds a M. Sc. in Biotechnology Engineering from the Ecole Supérieure de Biotechnologie(ESBS) de Strasbourg (France) and a PhD in Molecular Biology & Biochemistry specialized in Virology
from the University of Strasbourgco-directed with the University of Thessaly (Greece).

Sheik Mohammad Fazle Akbar

Principal Investigator, Toshiba General Hospital, Japan

Sheikh Mohammad Fazle Akbar has graduated in Medicine and Surgery from Bangladesh in 1980 and received his PhD in Medical Sciences from Japan in 1993. Being a post-graduate fellow from 1994-1996, he worked as full Faculty Member at the Graduate School of Medicine, Ehime University, Japan from 1996-2008. In 2008, he joined Toshiba General Hospital, Tokyo, Japan as Principal Investigator. He has worked to elucidate pathogenesis of chronic liver diseases and hepatocellular carcinoma; subsequently developed therapeutic vaccine for HBV transgenic mice and presently he has been conducting pilot studies and clinical trials in patients with CHB with Therapeutic Vaccines for last one decade to optimize a safe, effective and clinical viable regimen of this approach in CHB patients. He has authored more than one hundred scientific articles in peer-reviewed journals.

Ahmed Bouzidi

CEO, Vaxeal Group, Switzerland

AHMED BOUZIDI is the Chief Executive Officer Of Vaxeal Group, Vevey, Switzerland. He is also a Board Member of vaccines Europe - Brussels, Belgium. Ahmed Bouzidi is the founder of Vaxeal. He founded and managed SEDAC-Therapeutics inc., a leading biotech pioneer in peptide-based therapeutic vaccines (exit by Leveraged Buy Out), and Biophysiomics inc. (acquired by Chengdu Kuachang Science & Technology, China). He is a board member of Vaccines Europe and of the European Biopharmaceutical Enterprises (EBEbiopharma), and is a Senior Associate of the Royal Society of Medicine. He held previously senior advisory positions with Chinese pharmaceutical companies and public institutions, and worked 10 years as senior researcher at the LFB. He holds a Master degree in Animal Biology (University of Lille, France), a PhD in Cellular Biology, and a MBA in Finance (University of New Hampshire, USA)

About Conference


It is with immense pleasure and a great honor; we would like to welcome you all to participate at our conference on 3rd Edition of Global Cancer Meet & Expo Hybrid (Onsite and Online) to be held during April 27-29, 2023 in Amsterdam, Netherlands.

The conference is hosted by Linkin Science. These conferences are well crafted and designed by a team of skilled experts. Our conferences are vast expanded into Medical, life sciences, health care, Engineering and other social sciences. Each conference, summit or executive briefing is tailored to the sector, topic and audience need. Our event structure varies depending on issue and market requirements featuring Keynote presentations, Oral talks, Poster presentations, young research forum, Exhibitions, roundtables and variable formats. Our mission is to bring the researchers on a common platform and provide opportunity for them to interact. This scientific networking helps for the betterment of science by exchanging the ideas in a broader way. Magnifying Scientific Knowledge by Sharing the research and ideas. We believe in accelerating the possibilities of novel discoveries and enhancement in scientific research, by connecting scientific community for knowledge sharing. Join us to redefine and explore new research, to provide a credible source to barter ideas for scientific studies besides transforming the true outcomes of a distinct scientific discovery and grab the attention for rare emerging technologies.

Importance and Scope:

Cancer Biology is rapidly expanding by playing a prominent role in many fields. This Conference is a platform to Industry, Academia, Researchers, Innovators to come together to discuss the research activities, advancements, ideas and exhibit latest cancer diagnosis products.

Cancer is a disease in which some of the body’s cells grow uncontrollably and spread to other parts of the body. Cancer can start almost anywhere in the human body, which is made up of trillions of cells. A correct cancer diagnosis is essential for appropriate and effective treatment because every cancer type requires a specific treatment regimen. Treatment usually includes surgery, radiotherapy, and/or systemic therapy (chemotherapy, hormonal treatments, targeted biological therapies). The latest advance in the fight against cancer includes synthetic biopsies to AI-powered detection. As a possible new technology for cancer treatment, gene editing with CRISPR takes months, not a year or two, to genetically modify T cells. A much faster treatment for patients and the potential for genetic medicine is groundbreaking. Cancer may never be able to cure completely, but scientists are optimistic that vaccines, personalized medicine and smart lifestyle choices will help prevent and treat a much greater proportion of cases than currently happens.

Benefits of attending the conference:

Global Cancer Meet & Expo 2023 Hybrid conference (Onsite & Online) offers a wonderful opportunity to meet and enhance new contacts in the field of Oncology, Cancer Biology & Genetics with invaluable networking time for you. It allows delegates to have issues addressed on Cancer and its causes, Cancer Molecular Targets, latest breakthrough on cancer treatments and global experts who are up to date with the latest developments in this particular field and provide information on new advancements and other technologies. This Hybrid conference features world renowned keynote speakers, plenary talks, young research forum, poster presentations, technical workshops, exhibitions and career guidance sessions.

Target Audience:

  • Cancer Biology, Researchers, Industry delegates & Students
  • Cancer Associations and Societies
  • Business Entrepreneurs
  • Oncologists/Chemists/ Radiologists/Immunologists
  • Junior/Senior research fellows of Cancer Biology/ Genetics/Cancer Therapeutics

Scientific Sessions


Cancer Biology and Genetics:

Cancer is a generic term for a large group of diseases that can affect any part of the body. Other terms used are malignant tumors and neoplasms. One defining feature of cancer is the rapid creation of abnormal cells that grow beyond their usual boundaries, and which can then invade adjoining parts of the body and spread to other organs; the latter process is referred to as metastasis. Widespread metastases are the primary cause of death from cancer. The Cancer biologist understand the biological processes underlying cancer initiation, progression, and metastasis. They identify how tumors evolve and respond to or resist treatment and study how cellular processes such as cancer cell metabolism, stress responses, and cell cycle regulation contribute to cancer development and progression. Cancer is a genetic disease. It is caused by changes in genes that control the way cells grow and multiply. Cancer-related genetic changes can occur because, random mistakes in our DNA happen as our cells multiply, our DNA is altered by carcinogens in our environment, such as chemicals in tobacco smoke, UV rays from the sun, and the human papillomavirus (HPV) they were inherited from one of our parents. Researchers continue to study how genetic changes affect cancer development. This knowledge has led to improvements in cancer care, including early detection, risk reduction, the use of targeted therapy, and survival. Researchers have learned a lot about how cancer genes work. But many cancers are not linked with a specific gene. Cancer likely involves multiple gene mutations. Moreover, some evidence suggests that genes interact with their environment. This further complicates our understanding of the role genes play in cancer.

Cancer and Aging:

There is a bidirectional relationship between cancer and aging. Aging is a risk factor for adult cancers, and emerging evidence suggests that cancers and some cancer treatments might accelerate aging. Aging and cancer share many hallmarks such as genomic instability, although cancer cells often benefit from mutations, other cells accumulate damaging mutations resulting in physiological decline and aging. Growing evidence demonstrates that individuals with cancer age faster, so their biological age appears to be older than their chronological age. Cancer survivors, in general, appear to develop age-related diseases and phenotypes sooner than members of the general population. This is likely because damage to normal tissues from cancer therapies diminishes physiological reserve, accelerates processes typically associated with ageing or both. Cancer treatment can help people of any age and age should never be the only factor considered in creating a treatment plan. But it is also known that cancer treatment may be more challenging and complicated for older adults. For example, older adults are more likely to experience serious side effects from treatment.

Cancer Organoids:

Tumor organoids have been proposed as a model system for precision medicine. Tumor organoids are 3D cell culture systems that are generated in vitro from surgically resected patients’ tumors. A cancer/tumor organoid, also known as a “cancer surrogate,”. The ability of tumor organoids to retain characteristics of the original tumor makes them unique for cancer research on an individual patient level. Hence, the idea to use tumor organoids for clinical decision making and optimize patient outcome is tempting. The cancer organotypic models help in understanding of cancer heterogeneity and its implications for personalized medicine. These advancements are, in part, attributed to the ability of organoid models to stably preserve genetic, proteomic, morphological and pharmacotypic features of the tumor in vitro, while also offering unprecedented genomic and environmental manipulation.

Cancer stem cells:

Cancer stem cells (CSCs) are cancer cells (found within tumors or hematological cancers) that possess characteristics associated with normal stem cells, specifically the ability to give rise to all cell types found in a particular cancer sample. CSCs may generate tumors through the stem cell processes of self-renewal and differentiation into multiple cell types. Such cells are hypothesized to persist in tumors as a distinct population and cause relapse and metastasis by giving rise to new tumors. Therefore, development of specific therapies targeted at CSCs holds hope for improvement of survival and quality of life of cancer patients, especially for patients with metastatic disease. Cancer stem cells were first identified in leukemia. The researchers discovered the first cancer stem cells in solid tumors, finding them in breast cancer. Since then, cancer stem cells have been identified in brain, colon, head and neck, pancreas and central nervous system tumors. Stem cells are defined by their ability to differentiate along multiple lineages and their immortality. Cancer is believed to be a stem cell disease in which a small population of cancer stem cells maintains the larger tumor. Cancer may ultimately be eradicated by targeting only the cancer stem cell.

CRISPR in Cancer Therapeutics

CRISPR” (pronounced “crisper”) stands for Clustered Regularly Interspaced Short Palindromic Repeats, which are the hallmark of a bacterial defense system that forms the basis for CRISPR-Cas9 genome editing technology. Genetic mutations that switch on oncogenes (gain-of-function mutations) stimulate carcinogenesis, and the expression of these oncogenes is specific to cancer cells. Knocking out these genes via CRISPR-Cas9 is an appealing therapeutic target because it will prevent cancer growth. Most of the designed strategies have been applied to detect cancer biomarkers in human serum or cell lysis. CRISPR-Cas9 can be employed to promptly engineer oncolytic viruses and immune cells for cancer therapeutic applications. More notably, it has the ability to precisely edit genes not only in model organisms but also in human being that permits its use in therapeutic analysis. CRISPR is becoming a mainstream methodology used in many cancers’ biology studies because of the convenience of the technique. CRISPR is also completely customizable. It can edit virtually any segment of DNA within the 3 billion letters of the human genome, and it’s more precise than other DNA-editing tools. And gene editing with CRISPR is a lot faster. With older methods. Another plus is that CRISPR can be easily scaled up. Researchers can use hundreds of guide RNAs to manipulate and evaluate hundreds or thousands of genes at a time. Cancer researchers often use this type of experiment to pick out genes that might make good drug targets. Taken together, the CRISPR/Cas system possesses great potential for cancer biomarker detection.

Computational Cancer Research, Data Science and Artificial Intelligence

Early cancer diagnosis and artificial intelligence (AI) are rapidly evolving fields with important areas of convergence. The application of AI in cancer practice includes providing clinical decision support for cancer diagnosis and screening, processing medical data for cancer detection or characterization of patient prognosis, and optimizing care delivery and clinical operations by increasing system capacity and allocating resources. AI identifies potential new drugs within a short time period at an affordable cost. Drug testing can simulate and predict the effectiveness of cancer therapies leading to better results in in vivo experiments, which in turn would accelerate clinical research. Scientists have developed AI tools to aid screening tests for several kinds of cancer, including breast cancer. AI-based computer programs have been used to help doctors interpret mammograms for more than 20 years, but research in this area is quickly evolving. AI can quickly understand how cancer cells become resistant to anticancer drugs, which can help improve drug development and adjust drug use. AI improves the identification of tumor neoantigens and the efficacy of tumor immunotherapy. It can help radiologists map target areas or automatically plan radiation treatment programs. AI can manage the use of chemotherapy drugs and predict the tolerance of chemotherapy drugs, so as to optimize the chemotherapy regimen.

Oncogenomics

Oncogenomics is a sub-field of genomics that characterizes cancer-associated genes. It focuses on genomic, epigenomic and transcript alterations in cancer. A mutated (changed) form of a type of gene called a proto-oncogene, which is involved in normal cell growth and division. When a proto-oncogene is changed so that too many copies are made or it becomes more active than normal, it is called an oncogene. Cancer is a genetic disease caused by accumulation of DNA mutations and epigenetic alterations leading to unrestrained cell proliferation and neoplasm formation. The goal of oncogenomics is to identify new oncogenes or tumor suppressor genes that may provide new insights into cancer diagnosis, predicting clinical outcome of cancers and new targets for cancer therapies. Besides understanding the underlying genetic mechanisms that initiate or drive cancer progression, oncogenomics targets personalized cancer treatment. Cancer develops due to DNA mutations and epigenetic alterations that accumulate randomly. Identifying and targeting the mutations in an individual patient may lead to increased treatment efficacy. Access to whole cancer genome sequencing is important to cancer genome research because: Mutations are the immediate cause of cancer and define the tumor phenotype. Access to cancerous and normal tissue samples from the same patient and the fact that most cancer mutations represent somatic events, allow the identification of cancer-specific mutations. Cancer mutations are cumulative and sometimes are related to disease stage. Metastasis and drug resistance are distinguishable.

Infection, Inflammation and Cancer types

Infection is one of the most common complications of cancer and cancer treatment. This is because cancer and cancer treatments can weaken the immune system for a period of time. More recently, infections with certain viruses, bacteria, and parasites have been recognized as risk factors for several types of cancer in humans. People with cancer who are treated with chemotherapy are more likely to get infections. The immune system helps our body protect itself from getting an infection. Cancer and chemotherapy can damage this system by reducing the number of infection-fighting white blood cells. Infections in cancer patients are often treated according to the germ that is causing them. Anti-infectives are drugs used to prevent or treat infections, for example: Antibiotics (sometimes more than one at the same time) are used to treat bacterial infections. Anti-fungal drugs are used to treat fungal infections. Inflammation is considered a hallmark of cancer. There is evidence that inflammation may both promote and constrain tumors. Inflammation can become chronic if the cause of the inflammation persists or certain control mechanisms in charge of shutting down the process fail. When these inflammatory responses become chronic, cell mutation and proliferation can result, often creating an environment that is conducive to the development of cancer. Cancers are named for the area in which they begin and the type of cell they are made of, even if they spread to other parts of the body. There are also several clinical terms used for certain general types of cancer. Carcinoma, this type of cancer affects organs and glands, such as the lungs, breasts, pancreas and skin. Sarcoma, this cancer affects soft or connective tissues, such as muscle, fat, bone, cartilage or blood vessels. Leukemia is a cancer of the bone marrow, which creates blood cells. Melanoma and Lymphoma, are cancers of the immune system.

Cancer and Public Health

Cancer is a large group of diseases that can start in almost any organ or tissue of the body when abnormal cells grow uncontrollably, go beyond their usual boundaries to invade adjoining parts of the body and/or spread to other organs. The latter process is called metastasizing and is a major cause of death from cancer. Cancer is the second leading cause of death globally. Lung, prostate, colorectal, stomach and liver cancer are the most common types of cancer in men, while breast, colorectal, lung, cervical and thyroid cancer are the most common among women. The cancer burden continues to grow globally, exerting tremendous physical, emotional and financial strain on individuals, families, communities and health systems. Many health systems in low- and middle-income countries are least prepared to manage this burden, and large numbers of cancer patients globally do not have access to timely quality diagnosis and treatment. The reality of cancer lies somewhere between the public health ideal of perfect prevention and the depressing stochastics of bad luck. Current research suggests that at least half of cancer cases estimates range from 30 percent to upward of 70 percent could be prevented by applying what we already know. The other half of cancer cases including the elusive and often deadly types often caught too late to make a difference, such as ovarian, pancreatic, and brain tumors could be detected and potentially even prevented far earlier if basic science and promising diagnostic technologies received the sustained government support, they need.

 

Market Analysis


Cancer diagnosis is a method of identifying different biomarkers, proteins and some signs that leads to the identification of the presence of a cancerous tumor. Efficient diagnostic testing is used to validate or rule out the existence of illness, monitor the progression of the disease and schedule & review treatment outcomes. Diagnostic procedure for cancer may include imaging, tumor biopsy, laboratory tests, surgery or genetic tsetiong. The increasing incidence of cancer across the globe and the growing use of biomarkers in tumor profiling are the primary growth drivers for this market. The global cancer diagnostics market size was valued at USD 160.5 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.89% from 2022 to 2030. Increasing number of cancer cases globally. and the demand for personalized medicine and the growing need for point of care diagnostics is one of the major factors contributing to industry growth during the forecast period.

Top Cancer biology Research centers, Organisations & Universities in Europe:

    • Institut Jules Bordet (IJB) (Brussels)
    • Department of Oncology / Comprehensive Cancer Centre at Helsinki University Central Hospital (HUCH) (Helsinki)
    • Centre Léon-Bérard (Lyon)
    • Institut Curie, Curie Institute (Paris)
    • Institut Gustave Roussy (Paris)
    • Maastricht University Medical Centre, (Maastricht)
    • Netherlands Cancer Institute (Amsterdam)
    • Universitair Medisch Centrum Groningen (UMCG), (Groningen)
    • Centro di Riferimento Oncologico at Istituto Nazionale Tumori (Aviano)
    • European Institute of Oncology (Milan)
    • Istituto Nazionale Tumori -IRCCS "Fondazione G.Pascale" (INT-Pascale) (Napoli)
    • Regina Elena National Cancer Institute (IRE) (Rome)
    • Institut Paoli-Calmettes, (Marseille)
    • Institut Universitaire du Cancer Toulouse Oncopole (Toulouse)
    • Karolinska Institute, Sweden
    • Erasmus University Rotterdam
    • University of Munich, Germany
    • Catholic University of Leuven, Belgium
    • University of Turin, Italy
    • Lund University, Sweden
    • University of Zurich, Switzerland

Top Cancer Companies and Industries in Europe

  • ADC Therapeutics
  • Affimed Therapeutics
  • BioNTech
  • Cellectis
  • Celyad
  • Ervaxx
  • Crescendo Biologics
  • Evaxion Biotech
  • GammaDelta Therapeutics
  • Genmab
  • Heidelberg Pharma
  • Hookipa Pharma
  • ImCheck
  • Immatics
  • Medigene
  • MorphoSys
  • NBE Therapeutics

Virtual Exhibitors


Exhibitors who would like to participate in Hybrid/Virtual mode, we provide a custom designed virtual trade booths. Companies who would like to participate onsite can send an email to  cancermeet@linkinscience.com or download the exhibitor brochure for detailed information.

Customizable Virtual Booths with the ability to upload logos, company offerings, social media presence, UNLIMITED files and videos for attendees to view. Immediate leads for any attendee that visits your booth or sets up a one-on-one virtual appointments. Opportunity to chat and communicate with attendees during LIVE virtual exhibit hours. With interactive features, that allow for video chats, pre-set appointments, and industry tours - the possibilities are endless!

REACH A LARGER AUDIENCE 
Attendees can access the Virtual Event from ANYWHERE - Bringing you relevant, diverse interactions with attendees from different market segments around the world. Meaning MORE attendees will get to see your company profile, products and services more efficiently.

GLOBAL PARTICIPATION – Attendees are not limited by their geographic locations – ALL parts of the world can attend!

COST-EFFECTIVE – Virtual Events provide the opportunity for additional staff participation and the opportunity to showcase additional products, services, and equipment.

CONVENIENT INTERACTIONS - Attendees will have the option to chat and communicate with a virtual expo representative during LIVE virtual exhibit hours. With interactive features, that allow for video chats, pre-set appointments, and industry tours.

Attendees will have dedicated time to visit exhibitors to learn about the latest products, services and solutions through literature, videos, social media, and meeting with representatives.

Corporate Exhibit Virtual Branding Package $1000

  • Post-Show Attendee List (emails  included)
  • Leads from attendees that set appointments and/or visit your booth (emails included)
  • Customizable Virtual Booth with ability to upload logos, company offerings, and social media presence
  • Company Logos with URL on Virtual Edition Website
  • The Attendee “Virtual Booth Crawl” – Attendees come to YOU!
  • Industry Tour - Company supplied 1-minute video posted on the event LOP website
  • Access to Virtual Leads & Sponsor Messaging: View list of attendees and send private messages to arrange appointments and virtually meet attendees via chat or on video
  • Enhanced Search Options for Attendees making it easy for them to search for your company name directly or by product categories


Why You Should Exhibit or Advertise at the Global Cancer Meet & Expo 2023 – The Hybrid Event:

MAXIMUM exposure to thousands of leads

Opportunity to acquire NEW customers that cannot attend events

Interact with attendees & capture VERIFIED LEADS with full contact information

Raise brand awareness with continuous promotion – even AFTER the show ends

Efficient spend on virtual event and marketing budget with limited staff time needed

BENEFITS OF HYBRID CONFERENCE


Hybrid Conference: This kind of event allows participants to join as per their convenience and choice of participation. It can be either onsite or Virtual; we ensure you have a wonderful learning experience at our events.

In-Person Attendance

Participants will be able to follow the physical sessions at the meeting halls. All the necessary precautions are taken at the event venue along with social distancing, sanitisation and wearing a mask is mandatory.

Virtual Attendance

Participants will be able to access the virtual content with the login information that will be sent to the e-mail address they have registered. We will project the virtual participant presentation on the screen and the talk will be delivered.

Participants can watch the presentation and send questions to the speaker or engage other delegates.

All conference presentations are broadcasted via webcast so you can watch from the comfort of your own office or home. All the features of an in-person event will still be available (Keynote sessions, Oral Presentations, Poster presentations, exhibit halls, networking, questions with presenters, downloadable collateral, etc.).

Exhibition

Virtual participants will be able to enter the virtual exhibition area and contact exhibiting companies by clicking on the name / logo of them. There will also be a physical exhibition area for the in-person participants.

Oral Presentation Sessions

During oral presentation sessions, speakers will present their works live within the specified time. The authors will also be able to make a virtual presentation if they cannot attend in-person.

Poster Presentation Sessions

Poster Presentations will be made in a PDF format accompanied by a video of a maximum of 10 minutes of the poster presenter. Attendees will have the opportunity to ask questions to the authors directly. The authors will also be able to make a virtual presentation if they cannot attend in-person.

Guidelines for Hybrid Conference


How will virtual participants access the Hybrid conference?

• Virtual attendees will receive an email with login instructions 3-5 days before the event. We encourage all attendees to log into the platform before the conference starts to make sure you can login. If you have trouble logging in, please email cancermeet@linkinscience.com.

• The conference will start at 9.30 am during the conference dates, so attendees should be logged into the virtual platform by 9:00 am.

What are the technical requirements for virtual participation?

• Laptop or personal computer

• Strong, reliable wifi connection

• Google Chrome is recommended to run the Virtual Conference platform.

Can I watch the live stream sessions on my phone or tablet or computer?

Yes, the Virtual Conference is accessible via a smart phone or tablet or computer/laptop.

Which sessions are going to be recorded?

All sessions will be recorded during the event and will be made available to attendees approximately 1-2 days after the event and be available for 12 months after release. Recordings will also include the session slides. If your registration includes access to the recordings, you will receive instructions for accessing them via email following the conference. Please refrain from personal recording as speakers may want to edit the recording before release.

Can I get a certificate of completion after attending virtual conference?

Yes, we will email soft copy of your certificate 2 days after the conference.

Where can I review the Program schedule of the online conference?

You can explore the speakers, topics, and schedule before the conference through agenda present in the website. This final agenda will be made available 5 days prior to the conference.

Can I ask the speaker a question or make a comment during a live session?

Questionnaire will there at end of each talk/presentation. Listeners can question and clarify their doubts. There will also be a chat box in which you can send messages for speakers to see.

Scientific Sessions

Abstract Submission : January 31, 2023

Early Bird Registration : January 31, 2023

  • Cancer Biology and Genetics
  • Cancer and Aging
  • Cancer Organoids
  • Cancer stem cells
  • CRISPR in Cancer Therapeutics
  • Computational Cancer Research, Data Science and Artificial Intelligence
  • Oncogenomics
  • Infection, Inflammation and Cancer types
  • Cancer and Public Health
  • Carcinogenic Exposures and Global Cancer Prevention
  • Tumor Immunology and Immunotheraphy
  • Imaging and RadioOncology
  • Cancer Disparities
  • Tumor invasion and metastasis
  • Precision cancer medicine and therapeutics
  • COVID-19 and Cancer
  • Pediatric Oncology
  • Metastatic Breast Cancer
  • Tissue regeneration & Oncology
  • Surgical & Clinical Oncology
  • Neuro-Oncology
  • Alternative medicine in Cancer treatment & Therapy
  • Tobacco control, Healthcare systems & policies
  • Regenerative Drugs market

Registration Categories

Abstract Submission : January 31, 2023

Early Bird Registration : January 31, 2023

Awards

Participants desiring to be considered for one of these awards need to specify their interest after their submission of the required abstract. Selected participants will be awarded under the following categories:

  1. Outstanding Submitted Abstract
  2. Best Research of the conference as evaluated by the Scientific Committee
  3. Best Poster of the conference depending on the rating given.
  4. Young Researcher Award under YRF category to encourage budding scientists/ researcher.

Selected participants will receive upto $1500 (USD) scholarship. Decisions will be made based on evaluation of the submitted abstract by the Scientific Committee. The decision made by the Scienctific Committe would be final. We want you to grab this opportunity and participate in the conference...!

Past Conference Report

Global Cancer Meet & Expo 2017 Past Conference Report:

Linkin Science has successfully completed Global Cancer Meet & Expo conference which was held during December 04-06, 2017 in Dubai. We thank all our expertise Scientific Committee Members who have been the constant support for the conference.

Linkin Science would like to greet all the Honourable guests, Keynote Speakers, Delegates, Media Partners and Exhibitors for their participation.

The keynote speakers include:

  • Xiaoping Sun, University of Texas MD Anderson Cancer Center, USA
  • Debananda Pati, Baylor College of Medicine, USA
  • Yun Gong, University of Texas MD Anderson Cancer Center, USA
  • Sheik Mohammad Fazle Akbar, Toshiba General Hospital, Japan
  • Ahmed Bouzidi ,CEO of Vaxeal Group, Switzerland

The Global Excellence award winners for Cancer Meet 2017 are:

  • Shafaq Maqsood, Shaukat Khanum Memorial Cancer hospital and Research, Pakistan (Poster category)
  • Ambreen Muzaffar, Shifa International Hospitals LTD, Pakistan (Poster Category)
  • Zarka Samoon, Aga Khan University Hospital, Pakistan (For Young Researcher Forum Category)

The 2nd Global Cancer Meet & Expo is scheduled during August 27-29, 2018 at ROME in ITALY. Hope to see you all at this international platform to explore your research in Oncology and Cancer research.

Global Cancer Meet & Expo 2018 Past Conference Report:

Linkin Science has successfully completed 2nd Global Cancer Meet & Expo conference which was held during August 27-28, 2018 in Rome, Italy. We thank all our expertise Scientific Committee Members who have been the constant support for the conference.

Linkin Science would like to greet all the Honourable guests, Keynote Speakers, Delegates, Media Partners and Exhibitors for their participation.

The keynote speakers include:

  • Debananda Pati, Baylor College of Medicine, USA
  • Aurelija Vaitkuviene, Vilnius University, Vilnius
  • Graeme Williams, Harvard, UK
  • Henrik G Bohr, Technical University of Denmark, Denmark
  • Shi-Ming Tu, Anderson Cancer Center, USA  

The 3rd Global Cancer Meet & Expo is scheduled during April 27-29, 2022 at Amsterdam, Netherlands. Hope to see you all at this international platform to explore your research in Oncology and Cancer research.